130 filings
Page 2 of 7
8-K
zpepsuixxab
10 Aug 23
Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
4:10pm
424B5
1ehxyvabaim027y7oxva
6 Jul 23
Prospectus supplement for primary offering
4:06pm
EFFECT
m42wade m2nqy
5 Jul 23
Notice of effectiveness
12:15am
CORRESP
vvovg 1qxo47
29 Jun 23
Correspondence with SEC
12:00am
UPLOAD
gujebe
29 Jun 23
Letter from SEC
12:00am
8-K
bcm6ydg6xb7zqjs9bw62
23 Jun 23
Entry into a Material Definitive Agreement
6:18pm
8-K
yryuzck 91lt68
23 Jun 23
Financial Statements and Supplementary Data
4:03pm
8-K
9t7nng8kum kl
11 May 23
Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results
4:11pm
ARS
1b44ab34cbnmi7gfbaz
28 Apr 23
Annual report to shareholders
4:14pm
DEFA14A
q0ka tnayharbd6
28 Apr 23
Additional proxy soliciting materials
4:11pm
8-K/A
q0atca 59m
21 Mar 23
Regulation FD Disclosure
4:06pm
S-8
vclj41n
1 Mar 23
Registration of securities for employees
4:56pm
8-K
xesjm91
1 Mar 23
Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million
4:06pm
425
suy24wg2z69vqq6
22 Feb 23
Business combination disclosure
4:48pm
8-K
q4r5b8pl73rx3z8n
22 Feb 23
Material Modifications to Rights of Security Holders
4:45pm
425
rs6bprzqraphb
13 Feb 23
Business combination disclosure
5:09pm
8-K
mimft97blcp 1e
13 Feb 23
Other Events
5:06pm